首页> 美国卫生研究院文献>American Health Drug Benefits >Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry

【2h】

Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry

机译：对最初的肿瘤坏死因子抑制剂反应不足的类风湿关节炎患者的延迟治疗加速：Corrona Registry的数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe implementation of treat-to-target principles in rheumatoid arthritis (RA) has not been fully investigated in patients with inadequate response to tumor necrosis factor (TNF) inhibitor treatment.

机译：背景技术对于肿瘤坏死因子（TNF）抑制剂治疗反应不足的患者，尚未全面研究类风湿关节炎（RA）中“按靶点治疗”原则的实施情况。

著录项

期刊名称 American Health Drug Benefits
作者
Dimitrios A. Pappas; Robert A. Gerber; Heather J. Litman; David Gruben; Jamie Geier; Winnie D. Hua; Connie Chen; Youfu Li; Joel M. Kremer; John S. Andrews; Jeffrey A. Bourret; Gary Branning; *;
展开▼
作者单位

展开▼
年(卷),期 2018(11),3
年度 2018
页码 148–158
总页数 11
原文格式 PDF
正文语种
中图分类药学;
关键词
arthritis Corrona registry registries response to therapy rheumatoid arthritis tumor necrosis factor inhibitor;

机译：关节炎;Corrona注册表;注册表;对治疗的反应;类风湿关节炎;肿瘤坏死因子抑制剂;

相似文献

外文文献
中文文献
专利

1. Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry [J] . Leslie R Harrold, George W Reed, Robert Magner, Arthritis research & therapy. . 2015,第1期

机译：在美国Corrona注册表中，类风湿关节炎患者先前接受过抗肿瘤坏死因子治疗后，利妥昔单抗与后续抗肿瘤坏死因子治疗的有效性和安全性比较
2. Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry [J] . Leslie R. Harrold, George W. Reed, Robert Magner, Arthritis research & therapy. . 2015,第Mara期

机译：Rituximab与随后的抗肿瘤坏死因子治疗的对比效果和安全性关节炎患者，以前暴露于美国科罗拉州注册表的抗肿瘤坏死因子疗法
3. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis [J] . Alberto Migliore, Giuseppe Pompilio, Davide Integlia, Therapeutic advances in musculoskeletal disease. . 2021,第a期

机译：肿瘤坏死因子抑制剂的循环与类风湿性关节炎患者对不同动作治疗的不同机制，对肿瘤坏死因子抑制剂的反应不足：贝叶斯网络荟萃分析
4. Lack of response to classic treatment is associated with anti-cyclic citrullinated peptide antibodies but not with drb1-se status in patients with recent-onset rheumatoid arthritis [C] . Manzanares B., Martinez F., Gonzalez R., European Congress of Immunology . 2009

机译：缺乏对经典治疗的反应与抗循环瓜氨酸肽抗体有关，但近期发病类风湿性关节炎的患者没有使用DRB1-SE状态
5. Predictors of Infection in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents [D] . Liu, Tasia 2017

机译：类风湿关节炎患者使用抗肿瘤坏死因子药物的感染预测因子
6. Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry [O] . Leslie R. Harrold, George W. Reed, Robert Magner, 2015

机译：在美国Corrona注册表中类风湿性关节炎患者在事先接受过抗肿瘤坏死因子治疗的情况下利妥昔单抗与后续抗肿瘤坏死因子治疗的有效性和安全性比较
7. Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry [O] . Leslie R. Harrold, George W. Reed, Robert Magner, 2015

机译：在美国Corrona注册表中，类风湿关节炎患者先前接受过抗肿瘤坏死因子治疗后，利妥昔单抗与随后的抗肿瘤坏死因子治疗的比较有效性和安全性

Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry

摘要

著录项

相似文献

相关主题

期刊订阅